Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;32(1):e2239.
doi: 10.1002/rmv.2239. Epub 2021 Apr 21.

Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials

Timothée Klopfenstein  1 , Vincent Gendrin  1 , N'dri Juliette Kadiane-Oussou  1 , Thierry Conrozier  2 , Souheil Zayet  1 ; HNF Hospital Tocilizumab Multidisciplinary Team
Affiliations
Review

Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials

Timothée Klopfenstein et al. Rev Med Virol. 2022 Jan.

Abstract

In this article, we express our opinion about tocilizumab as an effective treatment in coronavirus disease 2019, based on a narrative review and a deep analysis of tocilizumab randomised trial results. Eight trials were included. No one was in favour for controlled arm about main endpoint of death or mechanical ventilation incidence at day 28-30. Five trials on heterogenous populations seem to not demonstrate tocilizumab efficacy, but showed encouraging results in subgroup analysis on severe/critical patients (in favour for tocilizumab). Trials on severe/critical COVID-19 pneumonia as REMAP-CAP and RECOVERY showed mortality benefit of tocilizumab administration; CORIMUNO, REMAP-CAP and RECOVERY showed that tocilizumab decreased the incidence of mechanical ventilation. No safety signal about tocilizumab used was noticed in all trials. We concluded that tocilizumab reduces mortality and mechanical ventilation requirement if administered with the right timing in COVID-19 pneumonia. The challenge now is to define the optimal group and timing for tocilizumab benefit and we suggest that: (i) tocilizumab has a place in treatment of severe/critical COVID-19 pneumonia, with a high level of O2 flow or noninvasive ventilation or high flow nasal cannula; (ii) possibly early after intubation in patients on mechanical ventilation. Initiating tocilizumab in critically ill patients early before irreversible respiratory failure, especially in patients at an inflammatory stage could be the key to successful outcome.

Keywords: anti-interleukin-6; coronavirus disease 2019; randomised clinical trial; review; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Coronavirus Disease (COVID‐19) Dashboard. https://covid19.who.int. Accessed February 5, 2021.
    1. RECOVERY Collaborative Group , Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid‐19 – preliminary report. N Engl J Med. 2020. 10.1056/NEJMoa2021436 - DOI - PMC - PubMed
    1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID‐19 associated with acute respiratory distress syndrome Lancet Respir Med. 2020:8(4):420‐422. 10.1016/S2213-2600(20)30076-X - DOI - PMC - PubMed
    1. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID‐19): a meta‐analysis. Clin Chem Lab Med. 2020;58:1021. 10.1515/cclm-2020-0369 - DOI - PubMed
    1. Ruan Q, Yang K, Wang W, Jiang L, Song J. Correction to: Clinical predictors of mortality due to COVID‐19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:1294. 10.1007/s00134-020-06028-z - DOI - PMC - PubMed